USPTO serial 88044977
TURN THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 2, 2021
- Examiner
- GILLES, DEBORAH LYNN MEINERS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with TURN THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $748*
Plus Government fees of $650
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Calabasas, CA, US
Calabasas, CA, US
Calabasas, CA, US
Woodland Hills, CA, US
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents affecting sensory organs; Pharmaceutical agents for epidermis; Pharmaceutical agents for treating physically caused lesions; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical for the treatment of erectile dysfunction; Pharmaceutical preparation for skin care; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment and prevention of infectious diseases; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating dandruff; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for wounds; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, antivirals; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for pregnancy blemishes; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent stretch marks; Pharmaceutical products for ophthalmological use; Pharmaceutical products for skin care for animals; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Pharmaceutical skin lotions; Analgesic and muscle relaxant pharmaceutical preparations; Antibacterial pharmaceuticals; Balms for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for infectious diseases; Dermatological pharmaceutical products; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Ocular pharmaceuticals; Plant extracts for pharmaceutical purposes | ACTIVE | Jul 31, 2019 |
| 042 | Development of pharmaceutical preparations and medicines; Research and development in the pharmaceutical and biotechnology fields; Research on the subject of pharmaceuticals; Testing of pharmaceuticals | ACTIVE | Nov 30, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Global Health Solutions LLC
- Other trademarks owned by GLOBAL HEALTH SOLUTIONS, INC.
- Other trademarks owned by GLOBAL HEALTH SOLUTIONS, INC.
- Other trademarks owned by Global Health Solutions LLC
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named TURN THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 20, 2026 | PUM1 | OFFICE ACTION ISSUED POU1 | — |
| May 20, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 24, 2026 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Mar 2, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 2, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 28, 2021 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 27, 2021 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jan 27, 2021 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 25, 2021 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 6, 2021 | IUAF | USE AMENDMENT FILED | — |
| Jan 6, 2021 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Sep 2, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jul 10, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 8, 2020 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 8, 2020 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 8, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 4, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 2, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 2, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 2, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 9, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 5, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 5, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 5, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 29, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 29, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 8, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 13, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 13, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 24, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 9, 2018 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 8, 2018 | ALIE | ASSIGNED TO LIE | — |
| Sep 22, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 22, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 22, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 22, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 22, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 21, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 24, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 23, 2018 | NWAP | NEW APPLICATION ENTERED | — |